NIPH Clinical Trials Search

Zinc L-carnosine complex polaprezinc for pica and polydipsia

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Pica and polydipsia
Date of first enrollment	2015/03/09
Target sample size	20
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Polaprezinc 75 or 150 mg/day per os for 24 weeks.

Outcome(s)

Primary Outcome	Frequency of pica
Secondary Outcome	Severity of polydipsia assessed by diurnal weight gain and blood concentration of sodium Serum concentrations of BDNF and mature BDNF

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1) Malignant tumor 2) Chronic renal failure (estimated glomerular filtration rate, eGFR <45) 3) Other severe diseases 4) Terminal phase of an illness 5) History of taking polaprezinc or other zinc supplementation